TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 7-Day Multicenter Randomized Double-Blind, Double-Dummy Parallel Group Trial to Assess the Safety and Efficacy of 400 mg Lumiracoxib Once Daily Versus 500 mg Naproxen Twice Daily in Patients With Acute Musculoskeletal Pain Due to Uncomplicated Soft Tissue Injury
Brief Summary: This study is designed to develop our understanding of the risk-benefit of using lumiracoxib in patients with acute musculoskeletal pain due to uncomplicated soft tissue injury.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol, Drug: Ibuprofen placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen, Drug: Paracetamol Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol, Drug: Ibuprofen | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Paracetamol Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ibuprofen placebo; Assigned to Arm(s): 1
B: Arm Label: Oxycodone/acetaminophen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone/acetaminophen | Arm Label: Hydrocodone/acetaminophen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocodone/acetaminophen | Arm Label: Codeine/acetaminophen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Codeine/acetaminophen | Arm Label: Ibuprofen/acetaminophen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen/acetaminophen | Intervention Type: DRUG; Name: Oxycodone/acetaminophen; Assigned to Arm(s): Oxycodone/acetaminophen | Intervention Type: DRUG; Name: Hydrocodone/acetaminophen; Assigned to Arm(s): Hydrocodone/acetaminophen | Intervention Type: DRUG; Name: Codeine/acetaminophen; Assigned to Arm(s): Codeine/acetaminophen | Intervention Type: DRUG; Name: Ibuprofen/acetaminophen; Assigned to Arm(s): Ibuprofen/acetaminophen
C: Intervention Type: DRUG; Name: Lumiracoxib; Assigned to Arm(s): N/A
D: Arm Label: oral morphine and oral ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: oral morphine and oral ibuprofen | Arm Label: morphine and placebo of ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Oral morphine | Arm Label: ibuprofen and placebo of morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral ibuprofen | Intervention Type: DRUG; Name: oral morphine and oral ibuprofen; Assigned to Arm(s): oral morphine and oral ibuprofen | Intervention Type: DRUG; Name: Oral morphine; Assigned to Arm(s): morphine and placebo of ibuprofen | Intervention Type: DRUG; Name: Oral ibuprofen; Assigned to Arm(s): ibuprofen and placebo of morphine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Effect of the Angiotensin II Antagonist Valsartan on Diastolic Function in Patients With Hypertension and Diastolic Dysfunction
Brief Summary: Patients who have had high blood pressure for a long time may have diastolic dysfunction. Diastolic Dysfunction is when your heart has difficulty filling and emptying, and relaxing adequately.

This study is to find out if Valsartan) will improve the ability of the heart to fill, empty, and relax appropriately when given alone or with other medicines to treat high blood pressure.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: n-3 PUFA | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: n-3 PUFA; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Indapamide SR 1.5mg; Perindopril 2-4mg; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Valsartan; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension
Brief Summary: A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.


Options:
A: Arm Label: strict control; Type: ACTIVE_COMPARATOR; Interventions: Other: target blood pressure | Arm Label: moderate control; Type: ACTIVE_COMPARATOR; Interventions: Other: target blood pressure | Intervention Type: OTHER; Name: target blood pressure; Assigned to Arm(s): moderate control, strict control
B: Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP control | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Intervention Type: DRUG; Name: Intensive BP control; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Multifactorial vascular-risk-factor-intervention | Intervention Type: OTHER; Name: Multifactorial vascular-risk-factor-intervention; Assigned to Arm(s): 2
D: Arm Label: Benazepril/amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Arm Label: Benazepril/hydrochlorothiazide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Intervention Type: DRUG; Name: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1; Assigned to Arm(s): Benazepril/hydrochlorothiazide | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2; Assigned to Arm(s): Benazepril/hydrochlorothiazide | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Assigned to Arm(s): Benazepril/hydrochlorothiazide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension
Brief Summary: A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.


Options:
A: Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Delapril, Delapril-Manidipine Fixed combination; Assigned to Arm(s): N/A
C: Arm Label: Benazepril/amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Arm Label: Benazepril/hydrochlorothiazide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Intervention Type: DRUG; Name: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1; Assigned to Arm(s): Benazepril/hydrochlorothiazide | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2; Assigned to Arm(s): Benazepril/hydrochlorothiazide | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Assigned to Arm(s): Benazepril/hydrochlorothiazide
D: Intervention Type: DRUG; Name: Valsartan + amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Valsartan + HCTZ; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amlodipine + HCTZ; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Valsartan + amlodipine + HCTZ; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension
Brief Summary: A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.


Options:
A: Intervention Type: DRUG; Name: Amlodipine/atorvastatin single pill; Assigned to Arm(s): N/A
B: Arm Label: Caduet; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine besylate/atorvastatin calcium single pill combination | Intervention Type: DRUG; Name: Amlodipine besylate/atorvastatin calcium single pill combination; Assigned to Arm(s): Caduet
C: Arm Label: Benazepril/amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Arm Label: Benazepril/hydrochlorothiazide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Intervention Type: DRUG; Name: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1; Assigned to Arm(s): Benazepril/hydrochlorothiazide | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2; Assigned to Arm(s): Benazepril/hydrochlorothiazide | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Assigned to Arm(s): Benazepril/hydrochlorothiazide
D: Intervention Type: DRUG; Name: Amlodipine/Atorvastatin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate the Effectiveness of Valsartan 320 mg in Combination With Lisinopril 20 mg Versus Monotherapy With Lisinopril 40 mg or Valsartan 320 mg in Hypertensive Patients With Microalbuminuria on the Reduction of Urinary Albumin Creatinine Ratio
Brief Summary: The purpose of this study is to compare if the combination of valsartan 320 mg/lisinopril 20 mg versus the monotherapies of lisinopril 40 mg or valsartan 320 mg will result in a greater decrease of urinary albumin excretion measured as urinary albumin/creatinine ratio (UACR) in the first morning urine of hypertensive subjects with previously diagnosed microalbuminuria (MAU).


Options:
A: Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): N/A
B: Arm Label: Telmisartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Telmisartan | Arm Label: Enalapril; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan
C: Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A
D: Arm Label: A,AIIA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Candesartan and enalapril | Arm Label: A, ACE-I; Type: ACTIVE_COMPARATOR; Interventions: Drug: candesartan and enalapril | Arm Label: C, AIIA; Type: ACTIVE_COMPARATOR; Interventions: Drug: candesartan and enalapril | Arm Label: C, ACE; Type: ACTIVE_COMPARATOR; Interventions: Drug: candesartan and enalapril | Intervention Type: DRUG; Name: Candesartan and enalapril; Assigned to Arm(s): A,AIIA | Intervention Type: DRUG; Name: candesartan and enalapril; Assigned to Arm(s): A, ACE-I | Intervention Type: DRUG; Name: candesartan and enalapril; Assigned to Arm(s): C, AIIA | Intervention Type: DRUG; Name: candesartan and enalapril; Assigned to Arm(s): C, ACE

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670)in β-thalassemia Patients With Transfusional Iron Overload
Brief Summary: A 1-year randomized Phase III core trial (NCT00061750) using deferoxamine as the comparator was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older. Patients who successfully completed this main trial may continue in this extension trial to receive chelation therapy with deferasirox for an additional 4 years.

The objective of this study is to assess the efficacy and long-term safety of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older.


Options:
A: Arm Label: Deferiprone; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferoxamine | Intervention Type: DRUG; Name: Deferiprone; Assigned to Arm(s): Deferiprone | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Deferoxamine
B: Arm Label: ICL670 (Deferasirox); Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): ICL670 (Deferasirox)
C: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox
D: Arm Label: Deferiprone + Desferrioxamine; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (L1), Drug: Desferrioxamine | Arm Label: Deferiprone single agent; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (L1) | Arm Label: Desferrioxamine single agent; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desferrioxamine | Intervention Type: DRUG; Name: Deferiprone (L1); Assigned to Arm(s): Deferiprone + Desferrioxamine, Deferiprone single agent | Intervention Type: DRUG; Name: Desferrioxamine; Assigned to Arm(s): Deferiprone + Desferrioxamine, Desferrioxamine single agent

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670)in β-thalassemia Patients With Transfusional Iron Overload
Brief Summary: A 1-year randomized Phase III core trial (NCT00061750) using deferoxamine as the comparator was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older. Patients who successfully completed this main trial may continue in this extension trial to receive chelation therapy with deferasirox for an additional 4 years.

The objective of this study is to assess the efficacy and long-term safety of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older.


Options:
A: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox
B: Arm Label: ICL670 (Deferasirox); Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): ICL670 (Deferasirox)
C: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox, Radiation: HIDA | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Single Arm | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Single Arm | Intervention Type: RADIATION; Name: HIDA; Assigned to Arm(s): Single Arm
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferoxamine | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferasirox | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Arm 1, Arm 3 | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Arm 2, Arm 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluvastatin in the Therapy of Acute Coronary Syndrome
Brief Summary: This study is to evaluate the safety and efficacy of fluvastatin versus placebo, dosed shortly after or immediately when the coronary event occurs.


Options:
A: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: rosuvastatin calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluvastatin in the Therapy of Acute Coronary Syndrome
Brief Summary: This study is to evaluate the safety and efficacy of fluvastatin versus placebo, dosed shortly after or immediately when the coronary event occurs.


Options:
A: Arm Label: Fluvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluvastatin | Arm Label: Fluvastatin + Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluvastatin plus ezetimibe | Intervention Type: DRUG; Name: fluvastatin; Assigned to Arm(s): Fluvastatin | Intervention Type: DRUG; Name: Fluvastatin plus ezetimibe; Assigned to Arm(s): Fluvastatin + Ezetimibe
B: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
D: Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
Brief Summary: This study will test the efficacy and safety of topical diclofenac sodium gel in the treatment of knee osteoarthritis.


Options:
A: Intervention Type: DRUG; Name: Diclofenac topical sodium gel 1%; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ketoprofen in Diractin® | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: ketoprofen in Diractin® | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: celecoxib | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ketoprofen in Diractin®; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ketoprofen in Diractin®; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): 3
C: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
Brief Summary: This study will test the efficacy and safety of topical diclofenac sodium gel in the treatment of knee osteoarthritis.


Options:
A: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Diclofenac topical sodium gel 1%; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Diclofenac Sodium Gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Diclofenac Sodium Gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A

Answer: D